scholarly journals Association between survival time with metastatic breast cancer and aggressive end-of-life care

2017 ◽  
Vol 166 (2) ◽  
pp. 549-558 ◽  
Author(s):  
Melissa K. Accordino ◽  
Jason D. Wright ◽  
Sowmya Vasan ◽  
Alfred I. Neugut ◽  
Tal Gross ◽  
...  
2021 ◽  
Vol 23 (3) ◽  
pp. 238-247
Author(s):  
Rachel L. Brazee ◽  
Bethany D. Nugent ◽  
Susan M. Sereika ◽  
Margaret Rosenzweig

2015 ◽  
Vol 18 (1) ◽  
pp. 50-55 ◽  
Author(s):  
Tracey L. O'Connor ◽  
Nuttapong Ngamphaiboon ◽  
Adrienne Groman ◽  
Debra L. Luczkiewicz ◽  
Sarah M. Kuszczak ◽  
...  

2016 ◽  
Vol 19 (11) ◽  
pp. 1075-1080 ◽  
Author(s):  
Thomas Bramley ◽  
Vincent Antao ◽  
Orsolya Lunacsek ◽  
Kristin Hennenfent ◽  
Anthony Masaquel

2016 ◽  
Vol 52 (6) ◽  
pp. e152
Author(s):  
Jennifer Philip ◽  
Anna Collins ◽  
Jodie Burchell ◽  
Meinir Krishnasamy ◽  
Linda Mileshkin ◽  
...  

2020 ◽  
Vol 37 (10) ◽  
pp. 853-858
Author(s):  
Noriko Nogami ◽  
Katsuya Nakai ◽  
Yoshiya Horimoto ◽  
Akio Mizushima ◽  
Mitsue Saito

Background: Metastatic breast cancer (MBC) is generally incurable, but patients can survive longer than those with other cancer types. Treatment strategies for MBC are complex, and it is difficult to establish evidence of efficacy since symptoms and patient backgrounds vary markedly. Some patients struggle to decide where to receive end-of-life care, despite palliative care intervention, and some die in unexpected places. With the aim of ascertaining the best way to intervene on behalf of patients with end-stage breast cancer, we retrospectively examined interventions provided by our palliative care team. We investigated factors influencing the decision-making processes of patients with MBC regarding end-of-life care locations and where patients actually died. Methods: Clinical records of 44 patients with MBC, all Japanese women, who received palliative care interventions at our hospital, were retrospectively investigated. We examined factors, such as age, possibly impacting decision-making processes regarding the final location and actual place of death. Results: Thirty-five (80%) patients were able to decide where to receive end-of-life care, while the others were not. For these 35 patients, desired locations were the palliative care unit (77%), home palliative care (14%), and the hospital (9%). Age and recurrence-free survival (RFS) were factors influencing patients’ decision-making processes ( P = .030 and .044, respectively). Of the 35 patients, 25 (71%) were able to receive end-of-life care at their desired locations. Conclusions: Young patients and those with short RFS struggled with making decisions regarding where to receive end-of-life care. Such patients might benefit from prompt introduction of advanced care planning.


2005 ◽  
Vol 23 (33) ◽  
pp. 8322-8330 ◽  
Author(s):  
Ruth E. Langley ◽  
James Carmichael ◽  
Alison L. Jones ◽  
David A. Cameron ◽  
Wendi Qian ◽  
...  

Purpose To compare the effectiveness and tolerability of epirubicin and paclitaxel (EP) with epirubicin and cyclophosphamide (EC) as first-line chemotherapy for metastatic breast cancer (MBC). Patients and Methods Patients previously untreated with chemotherapy (except for adjuvant therapy) were randomly assigned to receive either EP (epirubicin 75 mg/m2 and paclitaxel 200 mg/m2) or EC (epirubicin 75 mg/m2 and cyclophosphamide 600 mg/m2) administered intravenously every 3 weeks for a maximum of six cycles. The primary outcome was progression-free survival; secondary outcome measures were overall survival, response rates, and toxicity. Results Between 1996 and 1999, 705 patients (353 EP patients and 352 EC patients) underwent random assignment. Patient characteristics were well matched between the two groups, and 71% of patients received six cycles of treatment. Objective response rates were 65% for the EP group and 55% for the EC group (P = .015). At the time of analysis, 641 patients (91%) had died. Median progression-free survival time was 7.0 months for the EP group and 7.1 months for the EC group (hazard ratio = 1.07; 95% CI, 0.92 to 1.24; P = .41), and median overall survival time was 13 months for the EP group and 14 months for the EC group (hazard ratio = 1.02; 95% CI, 0.87 to 1.19; P = .8). EP patients, compared with EC patients, had more grade 3 and 4 mucositis (6% v 2%, respectively; P = .0006) and grade 3 and 4 neurotoxicity (5% v 1%, respectively; P < .0001). Conclusion In terms of progression-free survival and overall survival, there was no evidence of a difference between EP and EC. The data demonstrate no additional advantage to using EP instead of EC as first-line chemotherapy for MBC in taxane-naïve patients.


Sign in / Sign up

Export Citation Format

Share Document